Does whole orbital tissue culture identify imatinib mesylate and adalimumab as potential therapeutics for Graves ' ophthalmopathy?
Imatinib mesylate can be expected to reduce inflammation and tissue remodelling in GO, while adalimumab can be mainly expected to reduce inflammation. This in vitro tissue-culture model may, in future, prove valuable to test novel therapeutics for their presumed effect in GO as well as in other inflammatory diseases.
Endometrial carcinoma/atypical hyperplasia were commonly observed in GCT patients>40years; based on these data, endometrial sampling should be performed in symptomatic women at least 40years of age. In asymptomatic women<40years, endometrial sampling is of low yield.